Loading…

Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test

In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors wit...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 1989-09, Vol.80 (9), p.833-839
Main Authors: Kwon, Kil‐Won, Ikeda, Hisami, Yano, Misako, Sekiguchi, Sadayoshi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623
cites cdi_FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623
container_end_page 839
container_issue 9
container_start_page 833
container_title Cancer science
container_volume 80
creator Kwon, Kil‐Won
Ikeda, Hisami
Yano, Misako
Sekiguchi, Sadayoshi
description In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors with age. Among the PA‐positive donors in the 50–64 age group, 65.9% were IF‐positive compared to 16.0% in the 16–19 age group. The serological specificities of the IF‐negative/ PA‐positive specimens were tested by using a newly developed PA inhibition (PAD test. The HTLV‐I specificity of the PAI test was confirmed by the observation that agglutinations with anti‐HTLV‐I p19 and gp21 monoclonal antibodies as well as IF‐positive sera were specifically inhibited with HTLV‐I preparations or HTLV‐I‐positive cell extracts and not with HTLV‐I‐negative cell extracts. Sixty of the 104 specimens collected randomly from the IF‐negative/PA‐positive donors were PAI‐positive. The majority (80%) of such PAI‐positive sera showed more than two bands of HTLV‐I gag‐encoded polypeptide, p19, p24, p2S and p53 on Western blotting. Some of the PAI‐positive sera were also positive by enzyme immunoassay. These results indicate that at least some of the IF‐negative/ PA‐positive donors possess HTLV‐I‐specific antibody and may be potential HTLV‐I carriers who will become IF‐positive at a later age
doi_str_mv 10.1111/j.1349-7006.1989.tb01723.x
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5917853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2400010414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623</originalsourceid><addsrcrecordid>eNqVUs2O0zAYtBBoKYVHQLIAcUuw49ipOSCVbmErVQKJwtVyXLt1SeNiJ93NDYkX4Bl5EpxtVH4uCPtgSzPf-PN8A8ATjFIc14tdiknOkwIhlmI-4WlTIlxkJL25A0Zn6C4YIY5RQhFF98GDEHYoshDLLsBFRjEhCI3At_lRVq1srKuhM7DZanjV7mUNVz--fp_pqoJL3X7WeyvhJ-vbAFfdQcMF_KC9O7hgG3u0TdeXvq6cW8NLVzsfYNndSr2XvrGq0nC62VRtY-vTQ4t6a0t7e13p0DwE94ysgn40nGPw8c18NbtKlu_eLmbTZaIoJyTBujRc0VIahllGGNMmY6agTMVtZImkpGZd5qbIFaOcl7zQeEKVRtGadawYg1cn3UNb7vVa6brxshIHb_fSd8JJK_5EarsVG3cUlONiQkkUeD4IePeljZ2LvQ0qmiRr7dogCk44Iwz_k4gpZTmKvxqDp38Rd671dXRBZDmK80I5ziPr5YmlvAvBa3PuGSPRJ0LsRD920Y9d9IkQQyLETSx-_Puvz6VDBCL-bMBlULIyXtbKhjONFSRDWfHLvGtb6e4_GhCz6XxCCPkJMCrVlw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2400010414</pqid></control><display><type>article</type><title>Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Kwon, Kil‐Won ; Ikeda, Hisami ; Yano, Misako ; Sekiguchi, Sadayoshi</creator><creatorcontrib>Kwon, Kil‐Won ; Ikeda, Hisami ; Yano, Misako ; Sekiguchi, Sadayoshi</creatorcontrib><description>In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors with age. Among the PA‐positive donors in the 50–64 age group, 65.9% were IF‐positive compared to 16.0% in the 16–19 age group. The serological specificities of the IF‐negative/ PA‐positive specimens were tested by using a newly developed PA inhibition (PAD test. The HTLV‐I specificity of the PAI test was confirmed by the observation that agglutinations with anti‐HTLV‐I p19 and gp21 monoclonal antibodies as well as IF‐positive sera were specifically inhibited with HTLV‐I preparations or HTLV‐I‐positive cell extracts and not with HTLV‐I‐negative cell extracts. Sixty of the 104 specimens collected randomly from the IF‐negative/PA‐positive donors were PAI‐positive. The majority (80%) of such PAI‐positive sera showed more than two bands of HTLV‐I gag‐encoded polypeptide, p19, p24, p2S and p53 on Western blotting. Some of the PAI‐positive sera were also positive by enzyme immunoassay. These results indicate that at least some of the IF‐negative/ PA‐positive donors possess HTLV‐I‐specific antibody and may be potential HTLV‐I carriers who will become IF‐positive at a later age</description><identifier>ISSN: 0910-5050</identifier><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>EISSN: 1876-4673</identifier><identifier>DOI: 10.1111/j.1349-7006.1989.tb01723.x</identifier><identifier>PMID: 2513300</identifier><identifier>CODEN: GANNA2</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Age ; Age Factors ; Agglutination ; Agglutination Tests ; AIDS/HIV ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antigens, Viral - analysis ; Biological and medical sciences ; Blood donor ; Blood Donors ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Carrier State - microbiology ; Enzyme immunoassay ; Fluorescent Antibody Technique ; Gag protein ; Gelatin ; HTLV-I Infections - microbiology ; HTLV‐I seroscreening ; Humans ; Immunoenzyme Techniques ; Immunofluorescence ; Medical sciences ; Middle Aged ; Monoclonal antibodies ; p53 Protein ; PAI ; PA‐positive/IF‐negative ; Serologic Tests ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Western blotting</subject><ispartof>Cancer science, 1989-09, Vol.80 (9), p.833-839</ispartof><rights>1990 INIST-CNRS</rights><rights>Copyright John Wiley &amp; Sons, Inc. Sep 1989</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623</citedby><cites>FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2400010414/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2400010414?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25728,27898,27899,36986,44563,53763,53765,75093</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=6732027$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2513300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kwon, Kil‐Won</creatorcontrib><creatorcontrib>Ikeda, Hisami</creatorcontrib><creatorcontrib>Yano, Misako</creatorcontrib><creatorcontrib>Sekiguchi, Sadayoshi</creatorcontrib><title>Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test</title><title>Cancer science</title><addtitle>Jpn J Cancer Res</addtitle><description>In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors with age. Among the PA‐positive donors in the 50–64 age group, 65.9% were IF‐positive compared to 16.0% in the 16–19 age group. The serological specificities of the IF‐negative/ PA‐positive specimens were tested by using a newly developed PA inhibition (PAD test. The HTLV‐I specificity of the PAI test was confirmed by the observation that agglutinations with anti‐HTLV‐I p19 and gp21 monoclonal antibodies as well as IF‐positive sera were specifically inhibited with HTLV‐I preparations or HTLV‐I‐positive cell extracts and not with HTLV‐I‐negative cell extracts. Sixty of the 104 specimens collected randomly from the IF‐negative/PA‐positive donors were PAI‐positive. The majority (80%) of such PAI‐positive sera showed more than two bands of HTLV‐I gag‐encoded polypeptide, p19, p24, p2S and p53 on Western blotting. Some of the PAI‐positive sera were also positive by enzyme immunoassay. These results indicate that at least some of the IF‐negative/ PA‐positive donors possess HTLV‐I‐specific antibody and may be potential HTLV‐I carriers who will become IF‐positive at a later age</description><subject>Adolescent</subject><subject>Age</subject><subject>Age Factors</subject><subject>Agglutination</subject><subject>Agglutination Tests</subject><subject>AIDS/HIV</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antigens, Viral - analysis</subject><subject>Biological and medical sciences</subject><subject>Blood donor</subject><subject>Blood Donors</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Carrier State - microbiology</subject><subject>Enzyme immunoassay</subject><subject>Fluorescent Antibody Technique</subject><subject>Gag protein</subject><subject>Gelatin</subject><subject>HTLV-I Infections - microbiology</subject><subject>HTLV‐I seroscreening</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Immunofluorescence</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>p53 Protein</subject><subject>PAI</subject><subject>PA‐positive/IF‐negative</subject><subject>Serologic Tests</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Western blotting</subject><issn>0910-5050</issn><issn>1347-9032</issn><issn>1349-7006</issn><issn>1876-4673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqVUs2O0zAYtBBoKYVHQLIAcUuw49ipOSCVbmErVQKJwtVyXLt1SeNiJ93NDYkX4Bl5EpxtVH4uCPtgSzPf-PN8A8ATjFIc14tdiknOkwIhlmI-4WlTIlxkJL25A0Zn6C4YIY5RQhFF98GDEHYoshDLLsBFRjEhCI3At_lRVq1srKuhM7DZanjV7mUNVz--fp_pqoJL3X7WeyvhJ-vbAFfdQcMF_KC9O7hgG3u0TdeXvq6cW8NLVzsfYNndSr2XvrGq0nC62VRtY-vTQ4t6a0t7e13p0DwE94ysgn40nGPw8c18NbtKlu_eLmbTZaIoJyTBujRc0VIahllGGNMmY6agTMVtZImkpGZd5qbIFaOcl7zQeEKVRtGadawYg1cn3UNb7vVa6brxshIHb_fSd8JJK_5EarsVG3cUlONiQkkUeD4IePeljZ2LvQ0qmiRr7dogCk44Iwz_k4gpZTmKvxqDp38Rd671dXRBZDmK80I5ziPr5YmlvAvBa3PuGSPRJ0LsRD920Y9d9IkQQyLETSx-_Puvz6VDBCL-bMBlULIyXtbKhjONFSRDWfHLvGtb6e4_GhCz6XxCCPkJMCrVlw</recordid><startdate>198909</startdate><enddate>198909</enddate><creator>Kwon, Kil‐Won</creator><creator>Ikeda, Hisami</creator><creator>Yano, Misako</creator><creator>Sekiguchi, Sadayoshi</creator><general>Blackwell Publishing Ltd</general><general>Japanese Cancer Association</general><general>John Wiley &amp; Sons, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>198909</creationdate><title>Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test</title><author>Kwon, Kil‐Won ; Ikeda, Hisami ; Yano, Misako ; Sekiguchi, Sadayoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adolescent</topic><topic>Age</topic><topic>Age Factors</topic><topic>Agglutination</topic><topic>Agglutination Tests</topic><topic>AIDS/HIV</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antigens, Viral - analysis</topic><topic>Biological and medical sciences</topic><topic>Blood donor</topic><topic>Blood Donors</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Carrier State - microbiology</topic><topic>Enzyme immunoassay</topic><topic>Fluorescent Antibody Technique</topic><topic>Gag protein</topic><topic>Gelatin</topic><topic>HTLV-I Infections - microbiology</topic><topic>HTLV‐I seroscreening</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Immunofluorescence</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>p53 Protein</topic><topic>PAI</topic><topic>PA‐positive/IF‐negative</topic><topic>Serologic Tests</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kwon, Kil‐Won</creatorcontrib><creatorcontrib>Ikeda, Hisami</creatorcontrib><creatorcontrib>Yano, Misako</creatorcontrib><creatorcontrib>Sekiguchi, Sadayoshi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kwon, Kil‐Won</au><au>Ikeda, Hisami</au><au>Yano, Misako</au><au>Sekiguchi, Sadayoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test</atitle><jtitle>Cancer science</jtitle><addtitle>Jpn J Cancer Res</addtitle><date>1989-09</date><risdate>1989</risdate><volume>80</volume><issue>9</issue><spage>833</spage><epage>839</epage><pages>833-839</pages><issn>0910-5050</issn><issn>1347-9032</issn><eissn>1349-7006</eissn><eissn>1876-4673</eissn><coden>GANNA2</coden><abstract>In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors with age. Among the PA‐positive donors in the 50–64 age group, 65.9% were IF‐positive compared to 16.0% in the 16–19 age group. The serological specificities of the IF‐negative/ PA‐positive specimens were tested by using a newly developed PA inhibition (PAD test. The HTLV‐I specificity of the PAI test was confirmed by the observation that agglutinations with anti‐HTLV‐I p19 and gp21 monoclonal antibodies as well as IF‐positive sera were specifically inhibited with HTLV‐I preparations or HTLV‐I‐positive cell extracts and not with HTLV‐I‐negative cell extracts. Sixty of the 104 specimens collected randomly from the IF‐negative/PA‐positive donors were PAI‐positive. The majority (80%) of such PAI‐positive sera showed more than two bands of HTLV‐I gag‐encoded polypeptide, p19, p24, p2S and p53 on Western blotting. Some of the PAI‐positive sera were also positive by enzyme immunoassay. These results indicate that at least some of the IF‐negative/ PA‐positive donors possess HTLV‐I‐specific antibody and may be potential HTLV‐I carriers who will become IF‐positive at a later age</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>2513300</pmid><doi>10.1111/j.1349-7006.1989.tb01723.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0910-5050
ispartof Cancer science, 1989-09, Vol.80 (9), p.833-839
issn 0910-5050
1347-9032
1349-7006
1876-4673
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5917853
source Publicly Available Content Database; PubMed Central
subjects Adolescent
Age
Age Factors
Agglutination
Agglutination Tests
AIDS/HIV
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antigens, Viral - analysis
Biological and medical sciences
Blood donor
Blood Donors
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
Carrier State - microbiology
Enzyme immunoassay
Fluorescent Antibody Technique
Gag protein
Gelatin
HTLV-I Infections - microbiology
HTLV‐I seroscreening
Humans
Immunoenzyme Techniques
Immunofluorescence
Medical sciences
Middle Aged
Monoclonal antibodies
p53 Protein
PAI
PA‐positive/IF‐negative
Serologic Tests
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Western blotting
title Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-04T09%3A25%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20Human%20T%E2%80%90Cell%20Leukemia%20Virus%20Type%20I%20Seropositivity%20of%20Blood%20Donors%20by%20the%20Particle%20Agglutination%20Inhibition%20Test&rft.jtitle=Cancer%20science&rft.au=Kwon,%20Kil%E2%80%90Won&rft.date=1989-09&rft.volume=80&rft.issue=9&rft.spage=833&rft.epage=839&rft.pages=833-839&rft.issn=0910-5050&rft.eissn=1349-7006&rft.coden=GANNA2&rft_id=info:doi/10.1111/j.1349-7006.1989.tb01723.x&rft_dat=%3Cproquest_pubme%3E2400010414%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2400010414&rft_id=info:pmid/2513300&rfr_iscdi=true